1. Home
  2. RNAZ vs AMBO Comparison

RNAZ vs AMBO Comparison

Compare RNAZ & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • AMBO
  • Stock Information
  • Founded
  • RNAZ 2016
  • AMBO 2000
  • Country
  • RNAZ United States
  • AMBO United States
  • Employees
  • RNAZ N/A
  • AMBO N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • RNAZ Health Care
  • AMBO Real Estate
  • Exchange
  • RNAZ Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • AMBO 7.0M
  • IPO Year
  • RNAZ 2021
  • AMBO 2010
  • Fundamental
  • Price
  • RNAZ $9.11
  • AMBO $2.71
  • Analyst Decision
  • RNAZ Strong Buy
  • AMBO
  • Analyst Count
  • RNAZ 1
  • AMBO 0
  • Target Price
  • RNAZ $280.00
  • AMBO N/A
  • AVG Volume (30 Days)
  • RNAZ 26.1K
  • AMBO 11.6K
  • Earning Date
  • RNAZ 08-13-2025
  • AMBO 01-01-0001
  • Dividend Yield
  • RNAZ N/A
  • AMBO N/A
  • EPS Growth
  • RNAZ N/A
  • AMBO N/A
  • EPS
  • RNAZ N/A
  • AMBO 0.11
  • Revenue
  • RNAZ N/A
  • AMBO $9,392,000.00
  • Revenue This Year
  • RNAZ N/A
  • AMBO N/A
  • Revenue Next Year
  • RNAZ N/A
  • AMBO N/A
  • P/E Ratio
  • RNAZ N/A
  • AMBO $27.31
  • Revenue Growth
  • RNAZ N/A
  • AMBO 2.50
  • 52 Week Low
  • RNAZ $6.15
  • AMBO $1.00
  • 52 Week High
  • RNAZ $905.52
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 55.86
  • AMBO 51.36
  • Support Level
  • RNAZ $8.04
  • AMBO $2.25
  • Resistance Level
  • RNAZ $9.70
  • AMBO $3.25
  • Average True Range (ATR)
  • RNAZ 0.67
  • AMBO 0.29
  • MACD
  • RNAZ 0.27
  • AMBO 0.06
  • Stochastic Oscillator
  • RNAZ 75.08
  • AMBO 48.57

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

Share on Social Networks: